Rituximab Monotherapy versus Rituximab and Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune Retinopathy

PURPOSE: To study whether rituximab and bortezomib combination therapy is more effective than rituximab monotherapy in the treatment of non-paraneoplastic autoimmune retinopathy (npAIR). METHODS: Retrospective case series involving six patients with npAIR, taking either rituximab and bortezomib comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Maleki, Arash, Colombo, Amanda, Look-Why, Sydney, Peter Y Chang, BA;, Anesi, Stephen D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PUBLISHED BY KNOWLEDGE E 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806323/
https://www.ncbi.nlm.nih.gov/pubmed/36620716
http://dx.doi.org/10.18502/jovr.v17i4.12304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806323/
https://www.ncbi.nlm.nih.gov/pubmed/36620716
http://dx.doi.org/10.18502/jovr.v17i4.12304

Ejemplares similares